# Total revenue rose 8 per cent to $15.29 billion in the first three months of the year.

*biotech · news · 2026-04-29 · The Sunday Times*

## Key points

- AstraZeneca's Q1 revenue reached $15.29 billion, surpassing analyst expectations of $14.9 billion.
- Positive phase III data was reported for four programs, including new molecular entities and tozorakimab.
- Tozorakimab showed reduced moderate-to-severe COPD exacerbations in two phase III trials versus placebo.
- AstraZeneca is maintaining its targets for 2024 and its $80 billion annual sales goal by 2030.

**Companies:** AstraZeneca
**Countries:** United Kingdom, United States, China

[Read the full story on The Sunday Times](https://www.thetimes.com/business/companies-markets/article/cancer-drugs-helps-astrazeneca-beat-expectations-f5xvg6glw)

---

Canonical: https://newsio.io/n/91d2a32f-8b6b-4078-9766-5b92ec3b93c3/total-revenue-rose-8-per-cent-to-15-29-billion-in-the-first-three-months-of-the
Summarized by Newsio from The Sunday Times. https://newsio.io/how-it-works